1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

22 Feb 2022
Admin
News Article

Glaxosmithkline Pauses Maternal Respiratory Syncytial Virus Vaccine Clinical Trials And To Provide Update Soon

Glaxosmithkline Plc Announced That It Has Voluntarily Paused Enrolment And Vaccination In The Grace Phase Iii Trial (Nct04605159), Evaluating Its Potential Respiratory Syncytial Virus (Rsv) Maternal Vaccine Candidate, As Well As Two Other Trials Investigating This Candidate In Pregnant Women (Nct04980391, Nct05229068).The Grace Study Was Launched In 2020 And Evaluates The Safety Of Gsk'S Candidate Vaccine (Gsk38888660A) For Pregnant Mothers And Infants And How It Affects Infants Born To Vaccinated Mothers. The Product Contains A Recombinant Subunit Pre-Fusion Rsv Antigen That Has Shown Positive Safety And Immunogenicity Results In A Phase I/Ii Trial Presented At The Id Week Congress In October 2020.This Decision Was Made Following A Recommendation From The Independent Data Monitoring Committee Based On An Observation From A Routine Safety Assessment. Monitoring Safety Signals Is An Integral Part Of The Clinical Development Process For Potential New Vaccines.This Decision Does Not Impact The Ongoing Aresvi 006 Phase Iii Trial (Nct04886596) For Rsv Older Adults (60 Years And Above). This Trial Remains On Track With An Anticipated Data Readout In The First Half Of 2022.In Its Statement, Gsk Noted That Monitoring Safety Signals Is Part Of The Committee'S Routine Task And Is Vital To The Development Process. The Company Added That The Pause Does Not In Any Way Impact The Ongoing Aresvi 006 Phase Iii Study For Older Adults Aged 60 Years And Up And That It Remains On Schedule To Deliver Its First Data Readout In The First Half Of 2022.Glaxosmithkline Will Provide A Further Update On The Respiratory Syncytial Virus (Rsv) Maternal Vaccine Candidate In Due Course.Respiratory Syncytial Virus Is An Important Indication For Glaxosmithkline, With Investment In The Space Contributing To A Recent 34 Per Cent Jump In Spending On Vaccine R&D, And 2022 Is Shaping Up To Be A Key Year For Its Attempt To Claim A Significant Slice Of A Market Targeted By Rival Companies Including Astrazeneca, Sanofi And Pfizer.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!